Xanthohumol suppresses glioblastoma via modulation of Hexokinase 2 -mediated glycolysis
Jian Yuan, Gang Peng, Gelei Xiao, Zhuanyi Yang, Jun Huang, Qing Liu, Zhiquan Yang, Dingyang Liu · Journal of Cancer · 2020
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · article · 2020
Abstract
Deregulation of aerobic glycolysis is a common phenomenon in human cancers, including glioblastoma (GBM).In the present study, we demonstrated that the natural compound xanthohumol has a profound anti-tumor effect on GBM via direct inhibition of glycolysis.Xanthohumol suppressed cell proliferation and colony formation of GBM cells, and significantly impaired glucose metabolism via inhibiting Hexokinase 2 (HK2) expression.We demonstrated that down-regulation of c-Myc was required for xanthohumol-induced decrease of HK2.Xanthohumol destabilization of c-Myc, and promoted FBW7-mediated ubiquitination of c-Myc.Xanthohumol attenuated Akt activity and inhibited the activation of GSK3β, resulted in c-Myc degradation.Overexpression of Myr-Akt1 significantly rescued xanthohumol-mediated c-Myc inhibition and glycolysis suppression.Finally, the xanthohumol-mediated down-regulation of the PI3-K/Akt-GSK3beta-FBW7 signaling axis promoted the destabilization of c-Myc.Finally, the animal results demonstrated that xanthohumol substantially inhibited tumor growth in vivo.Collectively, xanthohumol appears to be a promising new anti-tumor agent with the therapeutic potential for GBM.
Open the resolved locator · 10.7150/jca.33045
Metadata licence: OpenAlex metadata (CC0)